表紙
市場調查報告書

抗瘧疾藥的全球市場 - 各類藥物·各流通管道:機會分析與產業預測 (2019∼2026年)

Antimalarial Drugs Market by Drug Class and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019-2026

出版商 Allied Market Research 商品編碼 938408
出版日期 內容資訊 英文 193 Pages
商品交期: 2-3個工作天內
價格
抗瘧疾藥的全球市場 - 各類藥物·各流通管道:機會分析與產業預測 (2019∼2026年) Antimalarial Drugs Market by Drug Class and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日期: 2020年03月05日內容資訊: 英文 193 Pages
簡介

全球抗瘧疾藥市場在2018年估算為7億1136萬美元,2026年將達10億1939萬6000美元的規模,並以4.6%的年複合成長率成長。市場成長的主要因素有發展中國家患病人數的增加,及新藥的研究開發,各國政府的對策強化等。

本報告提供全球抗瘧疾藥的市場相關分析,提供疾病·產品概要和市場基本結構·最新趨勢,主要的推動及阻礙市場要素,今後的市場機會,市場規模的實際成果值·預測值 (今後8年份),各類藥物·各流通管道·各地區的詳細趨勢,主要企業的簡介等相關調查。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要企業的定位
    • 主要的投資財源
  • 左右抗瘧疾藥產業/市場的主要原因
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會

第4章 抗瘧疾藥市場:各類藥物

  • 概況
    • 市場規模與其預測
  • 奎寧
  • 氯喹
  • 鳥嘌呤
  • 甲氟喹
  • 乙胺嘧啶
  • 其他

第5章 抗瘧疾藥市場:各流通管道

  • 概況
  • 醫院藥局
  • 零售藥局
  • 電子商務,其他流通管道

第6章 抗瘧疾藥市場:各地區

  • 概況
  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲

第7章 企業簡介

  • Alvizia Healthcare Pvt. Ltd.
  • Bayer AG.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Ipca Laboratories Ltd.
  • Merck & Co., Inc
  • NOVARTIS AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
  • Zydus Cadila
目錄
Product Code: A02427

The global antimalarial drugs market accounted for $711,360 thousand in 2018 and is expected to reach $1,019,396 thousand by 2026, registering a CAGR of 4.6% from 2019 to 2026.

Malaria is caused by the transmission of parasites belonging to genus plasmodium. These parasites are transmitted through the bite of female Anopheles mosquito, which then get lodged into liver. These parasites grow in liver and multiply to further invade the red blood cells where these parasites mature and rupture the blood cell to form merozoites. These merozoites then invade other red blood cells,causing symptoms such as high fever, fatigue, dizziness, and others.Thus, malaria is highly fatal if left untreated for a long period of time. Therefore, the drugs used in the treatment of malaria are called as antimalarial drugs. Furthermore, there are different types of antimalarial drugs available in the market, which include quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. In addition, these drugs can be purchased on prescription from different type of pharmacies such as hospital and retail pharmacies. Moreover, these drugs are also available on e-commerce websites.

The major factor that drives the growth of the antimalarial drugs market include rise in prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new antimalarial drugs are some of the factors that boost the growth of the market. However, lack of awareness regarding healthcare in developing countries is a major factor that restrains the growth of the antimalarial drugs market. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for the market expansion during the forecast period.

The antimalarial drugs market size is studied on the basis of drug class, distribution channel, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, and e-commerce & other distribution channel. Region wise, it is analyzed across North America (the U.S. and Canada), Europe (Germany, the UK, and rest of Europe), Asia-Pacific (China, India, and rest of Asia-Pacific), and LAMEA (Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global antimalarial drugsmarket trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Drug Class

  • Quinine
  • Chloroquine
  • Proguanil
  • Mefloquine
  • Pyrimethamine
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • E-Commerce & Other Distribution Channel

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Africa
    • Rest of LAMEA

List of key players profiled in the report:

  • Alvizia Healthcare Pvt. Ltd.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Ipca Laboratories Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
  • Zydus Cadila

LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)

  • Cipla Limited
  • Ajanta Pharma

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
    • 1.2.1. List of key players profiled in the report
  • 1.3. Research methodology
    • 1.3.1. Primary research
    • 1.3.2. Secondary research
    • 1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
  • 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Top player positioning
    • 3.2.1. Top investment pockets
  • 3.3. Key forces shaping antimalarial drugs industry/market
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of malaria
      • 3.4.1.2. Surge in healthcare expenditure worldwide
      • 3.4.1.3. Presence of large number of pipeline products
    • 3.4.2. Restraint
      • 3.4.2.1. Poor demand in underdeveloped countries
    • 3.4.3. Opportunity
      • 3.4.3.1. High growth potential in developing economies
    • 3.4.4. Impact Analyses

CHAPTER 4: ANTIMALARIAL DRUGS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Quinine
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market analysis, by country
  • 4.3. Chloroquine
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market analysis, by country
  • 4.4. Proguanil
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market analysis, by country
  • 4.5. Mefloquine
    • 4.5.1. Key market trends, growth factors, and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market analysis, by country
  • 4.6. Pyrimethamine
    • 4.6.1. Key market trends, growth factors, and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market analysis, by country
  • 4.7. Others
    • 4.7.1. Key market trends, growth factors, and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market analysis, by country

CHAPTER 5: ANTIMALARIAL DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital pharmacy
    • 5.2.1. Market size and forecast, by region
    • 5.2.2. Market analysis, by country
  • 5.3. Retail Pharmacy
    • 5.3.1. Market size and forecast, by region
    • 5.3.2. Market analysis, by country
  • 5.4. E-commerce & other distribution channels
    • 5.4.1. Market size and forecast, by region
    • 5.4.2. Market analysis, by country

CHAPTER 6: ANTIMALARIAL DRUGS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends and opportunities
    • 6.2.2. Market analysis, by country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. market size and forecast, by drug class
      • 6.2.2.1.2. U.S. market size and forecast, by distribution channel
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada market size and forecast, by drug class
      • 6.2.2.2.2. Canada market size and forecast, by distribution channel
    • 6.2.3. North America market size and forecast, by drug class
    • 6.2.4. North America market size and forecast, by distribution channel
  • 6.3. Europe
    • 6.3.1. Key market trends and opportunities
    • 6.3.2. Market analysis, by country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany market size and forecast, by drug class
      • 6.3.2.1.2. Germany market size and forecast, by distribution channel
      • 6.3.2.3. UK
      • 6.3.2.3.1. UK market size and forecast, by drug class
      • 6.3.2.3.2. UK market size and forecast, by distribution channel
      • 6.3.2.4. Rest of Europe
      • 6.3.2.4.1. Rest of Europe market size and forecast, by drug class
      • 6.3.2.4.2. Rest of Europe market size and forecast, by distribution channel
    • 6.3.3. Europe market size and forecast, by drug class
    • 6.3.4. Europe market size and forecast, by distribution channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends and opportunities
    • 6.4.2. Market analysis, by country
      • 6.4.2.2. China
      • 6.4.2.2.1. China market size and forecast, by drug class
      • 6.4.2.2.2. China market size and forecast, by distribution channel
      • 6.4.2.3. India
      • 6.4.2.3.1. India market size and forecast, by drug class
      • 6.4.2.3.2. India market size and forecast, by distribution channel
      • 6.4.2.4. Rest of Asia-Pacific
      • 6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by drug class
      • 6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by distribution channel
    • 6.4.3. Asia-Pacific market size and forecast, by drug class
    • 6.4.4. Asia-Pacific market size and forecast, by distribution channel
  • 6.5. LAMEA
    • 6.5.1. Key market trends and opportunities
    • 6.5.2. Market analysis, by country
      • 6.5.2.1. Africa
      • 6.5.2.1.1. Africa market size and forecast, by drug class
      • 6.5.2.1.2. Africa market size and forecast, by distribution channel
      • 6.5.2.2. Rest of LAMEA
      • 6.5.2.2.1. Rest of LAMEA market size and forecast, by drug class
      • 6.5.2.2.2. Rest of LAMEA market size and forecast, by distribution channel
    • 6.5.3. LAMEA market size and forecast, by drug class
    • 6.5.4. LAMEA market size and forecast, by distribution channel

CHAPTER 7: COMPANY PROFILES

  • 7.1. Alvizia Healthcare Pvt. Ltd.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product portfolio
  • 7.2. Bayer AG.
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product portfolio
    • 7.2.5. Business performance
    • 7.2.1. Key strategic moves and developments
  • 7.3. F. Hoffmann-La Roche Ltd.
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product portfolio
    • 7.3.5. Business performance
  • 7.4. GlaxoSmithKline Plc
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product portfolio
    • 7.4.5. Business performance
    • 7.4.6. Key strategic moves and developments
  • 7.5. Ipca Laboratories Ltd.
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Business performance
  • 7.6. Merck & Co., Inc
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product portfolio
    • 7.6.5. Business performance
  • 7.7. NOVARTIS AG
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product portfolio
    • 7.7.5. Business performance
  • 7.8. Pfizer Inc.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product portfolio
    • 7.8.5. Business performance
  • 7.9. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product portfolio
    • 7.9.5. Business performance
  • 7.10. Zydus Cadila
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product portfolio
    • 7.10.5. Business performance
    • 7.10.6. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL ANTIMALARIAL DRUGS MARKET, BY DRUG CLASS, 2018-2026 ($THOUSAND)
  • TABLE 02. QUININE ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 03. CHLOROQUINE ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 04. PROGUANIL ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 05. MEFLOQUINE ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 06. PYRIMETHAMINE ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 07. OTHERS ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 08. GLOBAL ANTIMALARIAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($THOUSAND)
  • TABLE 09. HOSPITAL PHARMACY ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 10. RETAIL PHARMACY ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 11. E-COMMERCE & OTHER DISTRIBUTION CHANNELS ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 12. ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
  • TABLE 13. NORTH AMERICA ANTIMALARIAL DRUGS MARKET REVENUE, BY COUNTRY, 2019-2026 ($THOUSAND)
  • TABLE 14. U.S. ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 15. U.S. ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 16. CANADA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 17. CANADA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 18. NORTH AMERICA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026($THOUSAND)
  • TABLE 19. NORTH AMERICA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 20. EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY COUNTRY, 2019-2026 ($THOUSAND)
  • TABLE 21. GERMANY ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 22. GERMANY ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 23. UK ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 24. UK ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 25. REST OF EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 26. REST OF EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 27. EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026($THOUSAND)
  • TABLE 28. EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026($THOUSAND)
  • TABLE 29. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY COUNTRY, 2019-2026 ($THOUSAND)
  • TABLE 30. CHINA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 31. CHINA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 32. INDIA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 33. INDIA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 34. REST OF ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 35. REST OF ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 36. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026($THOUSAND)
  • TABLE 37. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026($THOUSAND)
  • TABLE 38. LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY COUNTRY, 2019-2026 ($THOUSAND)
  • TABLE 39. AFRICA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 40. AFRICA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 41. REST OF LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026 ($THOUSAND)
  • TABLE 42. REST OF LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026 ($THOUSAND)
  • TABLE 43. LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019-2026($THOUSAND)
  • TABLE 44. LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019-2026($THOUSAND)
  • TABLE 45. ALVIZIA: COMPANY SNAPSHOT
  • TABLE 46. ALVIZIA HEALTHCARE PVT. LTD.: PRODUCT SEGMENTS
  • TABLE 47. ALVIZIA: PRODUCT PORTFOLIO
  • TABLE 48. BAYER: COMPANY SNAPSHOT
  • TABLE 49. BAYER: OPERATING SEGMENTS
  • TABLE 50. BAYER: PRODUCT PORTFOLIO
  • TABLE 51. ROCHE: COMPANY SNAPSHOT
  • TABLE 52. ROCHE: OPERATING SEGMENTS
  • TABLE 53. ROCHE: PRODUCT PORTFOLIO:
  • TABLE 54. GSK: COMPANY SNAPSHOT
  • TABLE 55. GSK: OPERATING SEGMENTS
  • TABLE 56. GSK: PRODUCT PORTFOLIO
  • TABLE 57. IPCA: COMPANY SNAPSHOT
  • TABLE 58. IPCA: OPERATING SEGMENTS
  • TABLE 59. IPCA: PRODUCT PORTFOLIO
  • TABLE 60. MERCK: COMPANY SNAPSHOT
  • TABLE 61. MERCK: OPERATING SEGMENTS
  • TABLE 62. MERCK: PRODUCT PORTFOLIO
  • TABLE 63. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 64. NOVARTIS: OPERATING SEGMENTS
  • TABLE 65. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 66. PFIZER: COMPANY SNAPSHOT
  • TABLE 67. PFIZER: OPERATING SEGMENTS
  • TABLE 68. PFIZER: PRODUCT PORTFOLIO
  • TABLE 69. SUN PHARMA.: COMPANY SNAPSHOT
  • TABLE 70. SUN PHARMA: OPERATING SEGMENTS
  • TABLE 71. SUN PHARMA: PRODUCT PORTFOLIO
  • TABLE 72. ZYDUS: COMPANY SNAPSHOT
  • TABLE 73. ZYDUS: OPERATING SEGMENTS
  • TABLE 74. ZYDUS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. GLOBAL ANTIMALARIAL DRUGS MARKET SEGMENTATION
  • FIGURE 02. TOP PLAYER POSITIONING, 2018
  • FIGURE 03. TOP INVESTMENT POCKETS
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. HIGH INTENSITY OF RIVALRY
  • FIGURE 08. LOW THREAT OF NEW ENTRANT
  • FIGURE 09. IMPACT ANALYSES, ANTIMALARIAL DRUGS MARKET
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF QUININE ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CHLOROQUINE ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PROGUANIL ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MEFLOQUINE ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PYRIMETHAMINE ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OTHERS ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF E-COMMERCE & OTHER DISTRIBUTION CHANNELS ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 19. U.S. ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 20. CANADA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 21. GERMANY ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 22. UK ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 23. REST OF EUROPE ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 24. CHINA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 25. INDIA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 26. REST OF ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 27. AFRICA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 28. REST OF LAMEA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
  • FIGURE 29. BAYER: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 30. BAYER: REVENUE SHARE BY SEGMENTS, 2018(%)
  • FIGURE 31. BAYER: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 32. ROCHE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 33. ROCHE: REVENUE SHARE BY SEGMENTS, 2018(%)
  • FIGURE 34. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 35. GSK: NET SALES, 2017-2018 ($MILLION)
  • FIGURE 36. GSK REVENUE SHARE BY SEGMENTS, 2018 (%)
  • FIGURE 37. GSK: REVENUE SHARE BY REGIONS, 2018 (%)
  • FIGURE 38. IPCA LABORATORIES LTD.: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 39. MERCK: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 40. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 41. MERCK: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 42. NET SALES, 2016-2018 ($MILLION)
  • FIGURE 43. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 44. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 45. PFIZER: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 46. PFIZER: REVENUE SHARE BY SEGMENT, 2018(%)
  • FIGURE 47. PFIZER: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 48. SUN PHARMA: NET SALES, 2018-2019 ($MILLION)
  • FIGURE 49. SUN PHARMA: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 50. ZYDUS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 51. ZYDUS: REVENUE SHARE BY REGION, 2019(%)